Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
- ByBenzinga-
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1...